Powder: -20°C for 3 years | In solvent: -80°C for 1 year
NCT-502 (N-(4,6-dimethylpyridin-2-yl)-4-[5-(trifluoromethyl)pyridin-2-yl]piperazine-1-carbothioamide) is a human phosphoglycerate dehydrogenase inhibitor, cytotoxic to PHGDH-dependent cancer cells. It decreases glucose-derived serine production and it has an IC50 of 3.7 μM against PHGDH.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | In stock | $ 33.00 | |
5 mg | In stock | $ 52.00 | |
10 mg | In stock | $ 79.00 | |
25 mg | In stock | $ 162.00 | |
50 mg | In stock | $ 253.00 | |
100 mg | In stock | $ 437.00 | |
500 mg | In stock | $ 982.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 57.00 |
Description | NCT-502 (N-(4,6-dimethylpyridin-2-yl)-4-[5-(trifluoromethyl)pyridin-2-yl]piperazine-1-carbothioamide) is a human phosphoglycerate dehydrogenase inhibitor, cytotoxic to PHGDH-dependent cancer cells. It decreases glucose-derived serine production and it has an IC50 of 3.7 μM against PHGDH. |
Targets&IC50 | PHGDH:3.7 μM |
In vitro | NCT-502 is cytotoxic to MDA-MB-468 (EC50: 15.2 μM)[1]. |
Synonyms | N-(4,6-dimethylpyridin-2-yl)-4-[5-(trifluoromethyl)pyridin-2-yl]piperazine-1-carbothioamide |
Molecular Weight | 395.45 |
Formula | C18H20F3N5S |
CAS No. | 1542213-00-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 0.1 mg/mL (insoluble)
DMSO: 125 mg/mL (316.10 mM), sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
NCT-502 1542213-00-2 Metabolism Dehydrogenase inhibit Inhibitor NCT502 N-(4,6-dimethylpyridin-2-yl)-4-[5-(trifluoromethyl)pyridin-2-yl]piperazine-1-carbothioamide NCT 502 inhibitor